We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




LTB Infection Estimated with Interferon-γ Release Assay

By LabMedica International staff writers
Posted on 01 Nov 2018
Latent tuberculosis (LTB), also called latent tuberculosis infection (LTBI) is when a person is infected with Mycobacterium tuberculosis, but do not have active tuberculosis. More...
Active tuberculosis can be contagious while latent tuberculosis is not, and it is therefore not possible to get infected from someone with latent tuberculosis.

In Japan, university students, including foreign-born students, undergo TB screening with chest radiograph; however, a chest radiograph cannot detect LTBI; it detects only pulmonary TB. Because immigrants may develop TB after entry, screening with chest radiograph might be ineffective; therefore, screening for LTBI may be necessary to prevent TB outbreaks.

Scientists at Keio University School of Medicine (Tokyo, Japan) and their colleagues enrolled 177 participants 20–42 years of age (median 23 years), of whom 98 (55.1%) were female. Participants were from China (55 students), Indonesia (24 students), France (19 students), Germany (nine students), and Thailand (eight students); the remaining participants were from 28 different countries; including 50 from countries with estimated TB incidence rates greater than 100 cases/100,000 persons.

The team collected whole blood specimens for the T-SPOT.TB test, an Interferon-γ Release Assay (IGRA) available in Japan. All participants were screened for pulmonary TB with chest radiograph. They interviewed participants using a structured questionnaire on identification and demographic information, the date of first arrival in Japan, and history of TB.

The scientists found that overall, eight (4.5%) students tested positive on IGRA (two each from China and Thailand and one each from Ghana, Indonesia, South Korea, and the Philippines). The rate of the positive IGRA result for students from countries with an estimated TB incidence rate of >100 cases/100,000 persons was 10.0% and relative risk was 4.2, whereas the rate for students from countries with an estimated TB incidence rate of <100 cases/100,000 persons was 2.4%. The IGRA positivity of students 20–29 years of age from countries with estimated TB incidence rates of >100 cases/100,000 persons was 9.4%.

The authors concluded that estimated LTBI rates for foreign-born students in Japan from countries with high TB incidence rates were higher than those for students from countries with low TB incidence rates and for students from Japan. Based on their findings, they recommend that universities screen for LTBI using IGRAs in students from countries with high TB incidence rates (i.e., >100 cases/100,000 persons). The study was published in the November 2018 issue of the journal Emerging Infectious Diseases.

Related Links:
Keio University School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.